Piet Ost: MDT vs ENRT and MDT for Nodal Oligorecurrent Prostate Cancer
Piet Ost, Radiation Oncologist at Iridium Network Antwerp, shared an article on X:
“STORM trial breaking results at ESTRO25!
MDT vs ENRT+MDT for nodal oligorecurrent PCa.
ENRT and MDT:
- Superior bRFS (57% vs 41%, p=0.014).
- Superior pelvic control (lrRFS 85% vs 62%, p=0.006).
- Superior MFS (76% vs 63%, p=0.06).
- No increase in ≥G2 GU/GI toxicity.”
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V–STORM): a phase 2, open-label, randomised controlled trial.
Authors: Piet Ost, Prof Shankar Siva, Sigmund Brabrand, Piet Dirix, Nick Liefhooghe, François-Xavier Otte, Alfonso Gomez-Iturriaga, Wouter Everaerts, Mohamed Shelan, Prof Antonio Conde-Moreno, Fernando López Campos, Alexandros Papachristofilou, Prof Matthias Guckenberger, Prof Marta Scorsetti, Almudena Zapatero, Ana-Elena Villafranca Iturre, Clara Eito, Prof Felipe Couñago, Paolo Muto, Wim Duthoy, Nicolas Mach, Valérie Fonteyne, Daniel Moon, Kristian Thon, Carole Mercier, Vérane Achard, Karin Stellamans, Prof Els Goetghebeur, Dries Reynders, Thomas Zilli.
You can read the Full Article on Journal of The Lancet Oncology.
More posts featuring Piet Ost.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023